Pacer Advisors Portfolio holdings
AUM
$39.6B
1-Year Return
5.04%
This Quarter Return
+9.61%
1 Year Return
+5.04%
3 Year Return
+42.86%
5 Year Return
+91.64%
10 Year Return
+332.32%
AUM
$43.5B
AUM Growth
+$8.16B
(+23%)
Cap. Flow
+$3.86B
Cap. Flow
% of AUM
8.88%
Top 10 Holdings %
Top 10 Hldgs %
11.55%
Holding
3,919
New
249
Increased
1,063
Reduced
1,013
Closed
119
Top Buys
| 1 |
Kenvue
KVUE
|
$439M |
| 2 |
AT&T
T
|
$437M |
| 3 |
Cummins
CMI
|
$427M |
| 4 |
Bunge Global
BG
|
$340M |
| 5 |
DaVita
DVA
|
$232M |
Top Sells
| 1 |
Qualcomm
QCOM
|
$453M |
| 2 |
AbbVie
ABBV
|
$447M |
| 3 |
Phillips 66
PSX
|
$441M |
| 4 |
D.R. Horton
DHI
|
$440M |
| 5 |
Booking.com
BKNG
|
$405M |
Sector Composition
| 1 | Consumer Discretionary | 17.42% |
| 2 | Energy | 16.95% |
| 3 | Industrials | 11.93% |
| 4 | Technology | 11.17% |
| 5 | Healthcare | 10.91% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1276
Denali Therapeutics
DNLI
$2.26B
| $41.6K | ﹤0.01% |
+2,025
| New | +$41.6K |
|
1277
Syndax Pharmaceuticals
SNDX
$1.47B
| $41.3K | ﹤0.01% |
+1,734
| New | +$41.3K |
|
1278
Arcellx
ACLX
$4.03B
| $41.2K | ﹤0.01% |
+593
| New | +$41.2K |
|
1279
Rocket Pharmaceuticals
RCKT
$354M
| $41.2K | ﹤0.01% |
+1,528
| New | +$41.2K |
|
|
SWTX
1280
DELISTED
SpringWorks Therapeutics
SWTX
| $41K | ﹤0.01% |
+834
| New | +$41K |
|
1281
IDEAYA Biosciences
IDYA
$2.38B
| $41K | ﹤0.01% |
+935
| New | +$41K |
|
1282
Amicus Therapeutics
FOLD
$2.46B
| $40.9K | ﹤0.01% |
+3,468
| New | +$40.9K |
|
1283
Marathon Digital Holdings
MARA
$5.63B
| $40.7K | ﹤0.01% |
+1,803
| New | +$40.7K |
|
1284
Apellis Pharmaceuticals
APLS
$3.55B
| $40.7K | ﹤0.01% |
+692
| New | +$40.7K |
|
1285
Biohaven
BHVN
$1.68B
| $40.3K | ﹤0.01% |
+737
| New | +$40.3K |
|
1286
Iovance Biotherapeutics
IOVA
$901M
| $40.3K | ﹤0.01% |
+2,716
| New | +$40.3K |
|
1287
Vaxcyte
PCVX
$4.29B
| $40.2K | ﹤0.01% |
+589
| New | +$40.2K |
|
|
SMAR
1288
DELISTED
Smartsheet Inc.
SMAR
| $40K | ﹤0.01% |
1,039
-31
| -3% | -$1.19K |
|
1289
PTC Therapeutics
PTCT
$4.55B
| $39.8K | ﹤0.01% |
+1,367
| New | +$39.8K |
|
1290
Kymera Therapeutics
KYMR
$3.11B
| $39.4K | ﹤0.01% |
+981
| New | +$39.4K |
|
1291
Intellia Therapeutics
NTLA
$1.29B
| $39.3K | ﹤0.01% |
+1,427
| New | +$39.3K |
|
1292
Ultragenyx Pharmaceutical
RARE
$3.07B
| $39.2K | ﹤0.01% |
+840
| New | +$39.2K |
|
1293
Simulations Plus
SLP
$279M
| $39.2K | ﹤0.01% |
953
+458
| +93% | +$18.8K |
|
1294
Twist Bioscience
TWST
$1.55B
| $39K | ﹤0.01% |
+1,138
| New | +$39K |
|
1295
TG Therapeutics
TGTX
$5.11B
| $38.7K | ﹤0.01% |
+2,542
| New | +$38.7K |
|
1296
Arcutis Biotherapeutics
ARQT
$2.06B
| $38.4K | ﹤0.01% |
+3,875
| New | +$38.4K |
|
|
NNDM
1297
Nano Dimension
NNDM
$293M
| $38.3K | ﹤0.01% |
13,751
-18
| -0.1% | -$50 |
|
1298
Recursion Pharmaceuticals
RXRX
$2.01B
| $38K | ﹤0.01% |
+3,812
| New | +$38K |
|
1299
Stratasys
SSYS
$871M
| $37.6K | ﹤0.01% |
3,238
-3
| -0.1% | -$35 |
|
1300
Nuvalent
NUVL
$5.83B
| $37.6K | ﹤0.01% |
+501
| New | +$37.6K |
|